GUJTHEM

Gujarat Themis Biosyn Share Price

 

 

Invest in Gujarat Themis Biosyn with 2.35X leverage

Invest with MTF

Performance

  • Low
  • ₹306
  • High
  • ₹320
  • 52 Week Low
  • ₹208
  • 52 Week High
  • ₹479
  • Open Price₹320
  • Previous Close₹319
  • Volume46,186
  • 50 DMA₹363.37
  • 100 DMA₹377.43
  • 200 DMA₹369.04

Investment Returns

  • Over 1 Month -15.63%
  • Over 3 Month -28.85%
  • Over 6 Month -10.67%
  • Over 1 Year + 21.39%

Smart Investing Starts Here Start SIP with Gujarat Themis Biosyn for Steady Growth!

Invest Now

Gujarat Themis Biosyn Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 73
  • PEG Ratio
  • -7.9
  • Market Cap Cr
  • 3,488
  • P/B Ratio
  • 13.2
  • Average True Range
  • 17.21
  • EPS
  • 4.39
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -17.02
  • RSI
  • 35.8
  • MFI
  • 32.9

Gujarat Themis Biosyn Financials

Gujarat Themis Biosyn Technicals

EMA & SMA

Current Price
₹320.10
+ 0.35 (0.11%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹336.17
  • 50 Day
  • ₹363.37
  • 100 Day
  • ₹377.43
  • 200 Day
  • ₹369.04

Resistance and Support

314.48 Pivot Speed
  • R3 328.87
  • R2 324.48
  • R1 318.87
  • S1 308.87
  • S2 304.48
  • S3 298.87

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Gujarat Themis Biosyn has an operating revenue of Rs. 159.33 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of 43% is great, ROE of 19% is exceptional. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 72 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Gujarat Themis Biosyn Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-05-20 Audited Results & Final Dividend
2025-02-14 Quarterly Results
Date Purpose Remarks
2025-09-05 FINAL Rs.0.67 per share(67%)Final Dividend
2024-02-22 INTERIM Rs.0.75 per share(75%)Interim Dividend
2022-12-02 INTERIM Rs.4.40 per share(88%)Interim Dividend
2021-11-25 INTERIM Rs.2.00 per share(40%)Interim Dividend
2021-11-25 SPECIAL Rs.5.00 per share(100%)Special Dividend
View Gujarat Themis Biosyn Dividend History Arrow
Date Purpose Remarks
2023-10-10 Split Rs.0.00 split from Rs. 5/- to Re. 1/-.
Date Purpose Remarks
2024-08-09 Bonus Re.0.00 issue in the ratio of 1:2 of Re. 1/-.

Gujarat Themis Biosyn F&O

Gujarat Themis Biosyn Shareholding Pattern

70.86%
1.16%
0%
1.96%
0.01%
19.9%
6.11%

About Gujarat Themis Biosyn

  • NSE Symbol
  • GUJTHEM
  • BSE Symbol
  • 506879
  • Managing Director
  • Dr. Sachin D Patel
  • ISIN
  • INE942C01045

Similar Stocks to Gujarat Themis Biosyn

Gujarat Themis Biosyn FAQs

Gujarat Themis Biosyn share price is ₹320 As on 14 February, 2026 | 04:04

The Market Cap of Gujarat Themis Biosyn is ₹3488 Cr As on 14 February, 2026 | 04:04

The P/E ratio of Gujarat Themis Biosyn is 73 As on 14 February, 2026 | 04:04

The PB ratio of Gujarat Themis Biosyn is 13.2 As on 14 February, 2026 | 04:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23